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Abstract In order to metastasize, cancer cells must first
detach from the primary tumor, migrate, invade through
tissues, and attach to a second site. Hakai was discovered as
an E3 ubiquitin-ligase that mediates the posttranslational down-
regulation of E-cadherin, a major component of adherens junc-
tions in epithelial cells that is characterized as a potent tumor
suppressor and is modulated during various processes includ-
ing epithelial–mesenchymal transition. Recent data have pro-
vided evidences for novel biological functional role of Hakai
during tumor progression and other diseases. Here, we will
review the knowledge that has been accumulated since Hakai
discovery 10 years ago and its implication in human cancer
disease. We will highlight the different signaling pathways
leading to the influence on Hakai and suggest its potential
usefulness as therapeutic target for cancer.
1 Introduction
Most of the human common tumors are carcinomas; which
arise from epithelial cells. Epithelial cells are connected to
each other by cell–cell contacts which determine cell polar-
ity and participate in cell differentiation and in the estab-
lishment and maintenance of tissue homeostasis. Cell–cell
contacts are regulated in epithelial cells during embryonic
development and in disease such as tumor development. For
instance, the downregulation of cell–cell adhesion is a hall-
mark characteristic of epithelia–mesenchymal transitions
(EMT), a process by which cells lose their polarized epithe-
lial phenotype and concomitantly acquire a migratory or
mesenchymal phenotype [1]. E-cadherin is the best charac-
terized and prototype member of the classical cadherins
in epithelial cells and is characterized as a potent tumor
suppressor, being considered hallmark of tumor malig-
nancy [2]. Epithelial tumors often lose E-cadherin par-
tially or completely as they progress toward malignancy
[3, 4]; and most studies have shown its anti-invasive
and antimetastatic roles [5, 6]. Given the huge impor-
tance of E-cadherin in cancer field, it has been exten-
sively studied the mechanisms involved on its inactivation in
human cancers; up to date, it has been addressed several
mechanisms: first, a genetic mechanism, such as inherited or
somatic mutations; second, epigenetic mechanism, such as
hypermethylation of E-cadherin promoter or transcription-
al silencing by different repressor including Twist, Snail,
and ZEB family members and their respective miRNA
regulators; and third, E-cadherin can also be regulated
by posttranslational modifications, such as phosphoryla-
tion, glycosylation, and proteolytic processing [7, 8]. In
2002, it was identified the first posttranslational regula-
tor of E-cadherin stability, named Hakai [9]; since then
many articles have described the emerging biological
functions for Hakai protein pointing out its influence
on tumor progression and disease. Here, we will review the
knowledge that has been accumulated since Hakai discovery
10 years ago.
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2 Hakai role at adherens junctions
In polarized epithelia of vertebrates, adhesion between epi-
thelial cells is mediated by distinct junctional complexes
named tight junctions, at the apical site, adherens junctions
(AJ) at the subapical site, and desmosomes, at basolateral
site [10]; these three types of junctions are linked to the
cytoskeletal filaments. Although all types of junctions are
functionally important, it has been shown that AJ are crucial
for the regulation of the dynamics of epithelial cell sheet and
can also transmit intracellular signals to the interior of the
cell under response of extracellular stimuli [11]. AJ are
adhesive structures that are regulated in a Ca2+-dependent
manner. Calcium-dependent junctions are constitute by a
group of type-I transmembrane proteins, and its founding
member was termed cadherin [12, 13]. Related molecules
identified were also called by several names, such as uvo-
morulin [14], L-CAM [15], and A-CAM [16]. Original
cadherins form a superfamily that is now called “classical”
cadherins; however, it has been discovered other members
(desmocollin, desmoglein, μ-protocadherin, CNR-cadherin,
seven transmembrane cadherin, T-cadherin, and FAT-family
cadherins) [17]; moreover, other proteins called nectins
were later identified as an AJ components, a family of
immunoglobulin-like transmembrane proteins that function
in a calcium-independent way to promote cell–cell adhesion
[18]. The classical cadherins comprises more than 20
members that contain a common organization domain. The
members are called E-cadherin (epithelial, Cdh1), N-
cadherin (neuronal, Cdh2), P-cadherin (placental, Cdh3),
and so on, each of which shows a distinct tissue distribution
[19]. The organization domain consists of an extracellular
domain and a cytoplasmic domain. The extracellular domain
is divided into five repetitive subdomains, also called cad-
herin repeats, and every subdomain contain calcium-binding
sequences [20]. On its association with calcium, the extra-
cellular domain of cadherins of a cell form homophilic
interactions with the extracellular domain of the cadherin
of neighboring cell (Fig. 1a, epithelial phenotype). The
cytoplasmic domain is highly conserved among classical
cadherins and interacts with cytosolic proteins called cate-
nins [21–23]. p120 and β-catenin (homologous to Drosoph-
ila melanogaster Armadillo) bind to the cytoplasmic tail of
the cadherins, and β-catenin binds to α-catenin to form the
cadherin–catenin complex. It has been shown that the link of
cadherin to the actin cytoskeleton is mediated through the
constant shuttling of α-catenin between cadherin/β-catenins
and actin which may be a key to explain the dynamic aspect
of cell–cell adhesion [24, 25]. Cadherin-based cell–cell con-
tacts are not static but are often dynamically modulated
during various physiological and pathological processes
including mitosis, epithelial–mesenchymal transition during
tumor progression and embryonic development. In all these
processes, cadherin has been reported to be downregulated
b- Fibroblast-like phenotype
E-cadherin
β - catenin
α - catenin
actin 
cytoeskeleton
p120-catenin
a- Epithelial phenotype
1
Src
P
2
Rab5
Rab7
3
4
Endocytic 
traffic
Lysosomes
Hakai
Ub
P
Fig. 1 Posttranslational mechanism to donwregulate E-cadherin at AJ
by Hakai. a Epithelial phenotype. E-cadherin contains five repetitive
subdomains to conform the extracellular domain by which it forms
homophilic interactions to the extracellular domain of the E-cadherin
of the neighboring cell. Its cytoplasmic domain contains two sequen-
ces: CH2 domain that interact with p120-catenin and the CH3 domain
interacting with β-catenin. It is also linked to the actin cytoeskeleton
through the dynamic shuttling of α-catenin between cadherin/β-cate-
nin and actin. b Fibroblastic-like phenotype induced by Hakai. After
tyrosine phosphorylation by Src in the cytoplasmic domain of E-
cadherin, Hakai induces the ubiquitination of the complex, following
endocytosis into vesicles through the action of Rab5 and Rab7 to
finally degrade into lysosomes, altering the integrity of cell–cell
contacts
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by endocytosis. In epithelial cells, activation of tyrosine
kinases such as epidermal growth factor receptor (EGFR),
the hepatocyte growth factor (HGF) receptor c-Met, the
fibroblast growth factor receptor or Src, induces cell scat-
tering and a fibroblast-like morphology [26, 27]. Met and
Src, respectively, have an active function in this process, as
they phosphorylate tyrosine residues in the cytoplasmic
domain of E-cadherin, thereby promoting its internalization
by endocytosis. Fujita et al. [9] underlined the molecular
mechanism responsible for this internalization. A new pro-
tein named Hakai (which means destruction in Japanese)
was identified as a responsible for the binding to the tyrosine
phosphorylated E-cadherin mediating its internalization and
subsequent ubiquitin-dependent degradation thereby alter-
ing cell–cell contacts. In the ubiquitination process, ubiqui-
tin moieties itself is involved and three different types of
enzymes: the ubiquitin-activating enzyme (E1), the
ubiquitin-conjugating enzyme (E2), and a variety of ubiq-
uitin ligases (E3). The E3 ubiquititn ligases provides the
specificity as they recognize the substrate through highly
specific protein–protein interactions [28]. Hakai, also
known as CBLL1, functions as an E3 ubiquitin ligase for
E-cadherin that binds to its cytoplasmic domain after tyrosin
phosphorylation by tyrosine kinase v-Src. The Src family
plays a pivotal role in the regulation of several biological
functions associated to changes in morphology, including
malignant transformation, cell plasticity, and modulation of
intercellular adhesion during EMT [29]. Hakai induces E2-
dependent ubiquitination of the E-cadherin complex fol-
lowed by endocytosis, disrupting cell–cell adhesions and
facilitating cell motility under physiological conditions. Al-
though the ubiquitination is one of the most general mech-
anisms to target cytosolic or nuclear proteins for degradation
via proteasome, many membrane proteins have triggered
degradation into lysosomes. The first work published in
Saccharomyces cerevisiae demonstrated that Ste2p, a G
protein-coupled cell surface receptor, undergone ligand-
dependent ubiquitination, following internalization into ves-
icle to be finally degraded into lysosomes [30]. In fact, it has
been shown that upon activation of Src in Madin-Darby
canine kidney (MDCK) cells, intracellular E-cadherin is
shuttled to the lysosomes for degradation, instead of follow-
ing normal route of the non-ubiquitinated E-cadherin that is
recycled back to the lateral plasma membrane to reform new
cell–cell contacts [31–33]. Indeed, the modification of E-
cadherin by ubiquitin is essential for its sorting to the
lysosomes, which occurs by a process mediated by hepato-
cyte growth factor receptor substrate and the activation of
specific Rab GTPases (Rab5 and Rab7). Rab5-GTP may
serve to enhance the rate of E-cadherin transport, and Rab7
activation may serve to shift the balance to endocytic traffic
toward the lysosomes. In consequence, cell–cell contacts do
not reform and cells remain motile which underlined the
first posttranslational mechanism to downregulate E-
cadherin during EMT (Fig. 1b, fibroblast-like phenotype)
[9–34].
Hakai protein was identified by using yeast 2-hybrid
screen of an E10.5 mouse cDNA library (on which a bait
vector containing an activated Met-kinase, trp-Met) fused to
the C-terminal sequence E-cadherin. The cytoplasmic do-
main of the E-cadherin contains two sequences, cadherin
homology 2 (CH2) and cadherin homology 3 (CH3)
domains, conserved between classical cadherins; respective-
ly [35, 36]. p120 and β-catenin can interact with these two
domains, respectively; however, its interaction does not
depend on the activation of trp-Met. Instead, Hakai interacts
with the all cytoplasmic domain, the CH2 domain contains
three closed tyrosine residues (in mouse: 756, 757, and
758), of which the first and second ones are specific for E-
cadherin and the third one is also conserved between cad-
herins, including N and OB cadherins. Hakai was unable to
interact with these two cadherins, neither with several tyro-
sine kinase receptors, suggesting that its binding is specific
on phosphorylated E-cadherin. By the identification of the
crystal structure of p120-catenin in complex with the frag-
ment of cadherin it was proposed that p120 might influence
the stability and function in cell–cell adhesion complexes
[37, 38]. p120-catenin can interact to the juxtamembrane
domain of E-cadherin (including tyrosine-phosphorylation
sites, where Hakai is also able to interact), therefore, it was
believed that the binding of p120 to the juxtamembrane
domain of cadherin block factors such as the ubiquitin-
ligase Hakai and components of the endocytic machinery,
which tag and target cadherin for destruction and internali-
zation [9, 37–39]. It was proposed that p120 associates with
cadherin through both “static” and “dynamic” interactions
over an extended stretch of the juxtamembrane domain. The
static interactions reflect strong interactions mediated by the
highly conserved core of the juxtamembrane domain, and
the dynamic interactions, presumably reflect interactions
with lower affinity. These motifs in the juxtamembrane
domain coincide with those linked to endocytosis by cla-
thrin or Hakai-associated mechanisms [37, 38]. The binding
sites for Hakai and p120 are closely apposed in the intracel-
lular juxtamembrane domain of E-cadherin and, accordingly,
p120 is displaced by the binding of Hakai to E-cadherin before
endocytosis [9]. Moreover, it is well-known that p120 is also
phosphorylated by Src kinase and receptor tyrosine kinases
[40] and that acidic pH activates c-Src [41]. An acidic extra-
cellular pH is a feature of the tumormicroenvironment and has
been associated with tumor behavior [42, 43]. Chen et al.
showed that acidic extracellular pH induced activation of Src
and Fyn and resulting in a tyrosine phosphorylation of E-
cadherin and p120 in HepG2 epithelial cells, which was
subsequently bound to Hakai and ubiquitin. In consequence,
an acidic pH is also weakening the association of E-cadherin
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and p120 and contributing to the instability of E-cadherin at
adherens junctions [41, 44].
3 In vivo studies of Hakai at adherens junctions
The functional role for Hakai in vivo came out in studies
carried out in D. melanogaster. Hakai is highly conserved in
metazoans, however, in Drosophila, Hakai did not interact
directly to the intracellular domain of Drosophila E-
cadherin, suggesting not only a different mode of associa-
tion between these proteins but also that Drosophila Hakai
does not play a major and direct role in downregulation of
E-cadherin levels [45]. As the structure of Drosophila Hakai
protein predicts cytoplasmic localization, its interaction to
Drosophila E-cadherin is likely indirect, involving at least
components that binds the cytoplasmic Hakai protein and
the extracellular or transmembrane domain of E-cadherin.
Indeed, Hakai overexpressed was absent from cell–cell
interfaces, but it localized with E-cadherin in cytoplasmic
vesicles that are different from known endosomal compart-
ments labeled with Rab5, Rab7, or Rab11. These results
suggested that Hakai coexist with E-cadherin in an intracel-
lular vesicle compartment that still has not been identified.
Only when E-cadherin was coexpressed together with
Hakai, they were both found enriched at cell–cell contacts
sites. Moreover, by in situ hybridization, Hakai mRNA
expression was highly detected in blastoderm stage embryos
and transcripts persisted up to stage 14; high levels of Hakai
mRNA was also detected in migrating endoderm cells, dis-
tributed through membranous structure in the cytoplasm,
perinuclear region, and the plasma membrane, suggesting
its possible implication in the migration of these cells over
the visceral mesoderm. As endoderm epithelia and visceral
mesoderm do not express E-cadherin, additional Drosophila
Hakai targets need to be identified and its possible implica-
tion in cell adhesion and migration in endoderm and visceral
development (for human Hakai substrates see below). In
addition, a number of proteins that can interact with Dro-
sophila Hakai were identified, underlying the importance of
aPKC and TNF-like protein IMD (immune deficiency). In
conclusion, that Hakai is essential for early embryonic mor-
phogenesis was demonstrated in Drosophila, and may also
be involved in regulating multiple target proteins that can
influence epithelial development in Drosophila [45].
4 Hakai molecular structure
E3 ubiquitin ligases contain motifs for recognizing specific
substrates proteins and are key control points for protein
ubiquitination. Up to now, the majority of the ubiquitin
ligases identified can be divided into two categories on
specific structural motifs: (A) those containing HECT do-
main and (B) those containing the RING-finger domain [46,
47]. The Cbl family ubiquitin ligase in mammals contains
three members: c-Cbl, Cbl-b, and Cbl-c. These members are
a single subunit RING-finger E3 containing several motifs
surrounding the RING finger: a highly conserved N-
terminal phosphor-Tyr binding (pTyr-B) domain that is
composed of a four-helix bundle, a calcium-binding domain
known as “EF hand”, and an atypical SH2 (Src homology 2)
domain. The pTyr-B domain mediates interactions between
CBL proteins and the phosphorylated residues on its CBL
substrates. The RING finger and pTyr-B domains are sepa-
rated by an α-helical linker region, important for the regu-
lation on its E3 ligase function. In the C-terminal region,
CBL proteins have proline-rich domains that mediate inter-
actions with SH3-containing proteins, and tyrosine that be-
come phosphorylated and mediate interactions with SH2
proteins [28]. In eukaryotic cells, phosphorylation regulates
cell signaling by pTyr-B domains typified by the SH2 and
pTyr-B (PTB) domains. By molecular modeling, it was
assumed that the pTyr-B domain of Hakai was a derivative
SH2 domain [9], (Fig. 2a). Hakai contains three domains: a
typical RING finger, a short pTyr-B domain, and a proline-
rich domain [9], considering that Hakai was structurally and
functionally related to c-Cbl. Hakai contains 491 amino
acids, sharing 97% homology between human and mouse
sequences. The predicted amino acid sequence at its N-
terminal contained a C3HC4-type RING finger domain, also
present in many E3 ubiquitin ligases [48, 49], and in the C-
terminal region, 35% of the amino acids are proline resi-
dues. However, Hakai and c-Cbl are not true homologues. A
recent study has deepened into the molecular structure of E3
ubiquitin-ligase Hakai highlighting a novel pTyr-B domain
[50]. This domain was named HYB (Hakai pTyr-binding)
and consists of a homodimer formed at a structurally novel
interface. Each monomer consists of two, a RING finger
domain and a short pTyr-B domain that incorporates an
atypical and novel zinc-finger coordination motif that incor-
porate connected configuration (Fig. 2b). Therefore, the
HYB is constituted by four zinc-binding domains that par-
ticipate to bind pTyr residues surrounded by acidic amino
acids [50]. The previously described target motif was in Src-
phophorylated E-cadherin, where two consecutive tyrosine
residues (Y753 and Y754 in humans) were reported to be
involved in the interaction with Hakai. They analyzed the
contribution of these tyr residues and conclude that the
phosphorylation of Y754 of the E-cadherin is the only
tyrosine significantly involved in the binding, and also that
a cluster of negative charges from acidic amino acids around
this Y754 of E-cadherin was also important. Indeed, they
have shown an important contribution from aspartic acid
(D756) and glutamic acid (E757), and significant contribu-
tions from valine (V752) and aspartic acid (D750). By mass
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spectrometry, they also identified a list of novel Hakai-
binding proteins phosphorylated by Src. They showed that
like E-cadherin, cortactin and DOK1 interact with Hakai
only when phosphorylated by Src. Moreover, they sug-
gested that this novel HYB identified was also present in
other proteins such as ZNF645, a testis-specific human E3
ubiquitin ligase [51], and possibly in Ligand-of-Numb pro-
tein X1 and 2 (LNX1 and LXN2). Hakai and ZNF645 share
significant homology, however ZNF645 bound to v-Src
phosphorylated E-cadherin but not to cortactin, indicating
that they likely have their own sets of targets due to differ-
ences found in their sequences between the key zinc-
coordinating residues. By tissue distribution, they also sug-
gest that ZNF645, found only in primates, is most likely a
recent copy of Hakai and an intronless, indicating that is a
retrotransposed copy of Hakai [50]. In conclusion, by com-
bining biochemical and crystal structural analyses, authors
demonstrated important mechanism by which E3 ubiquitin
ligase Hakai binds its targets molecules. They identified a
novel HYB domain that is present in other E3 ubiquitin
ligases proteins, often deregulated in cancer and other dis-
ease. Therefore, it is suggested that this HYB domain can
represent a specific target for directed therapies in cancer.
5 Hakai in response to oncogenic signaling pathways
Although it was demonstrated that Src expression regulates
ubiquitin-dependent E-cadherin lysosomal degradation [33],
it was no until 2008 when for the first time Shen et al.
reported upstream regulation [52]. It was previously estab-
lished that Src, and non-receptor kinase, is a central regula-
tor of signaling downstream of EGFR and it was also shown
to regulate EMT by disrupting adherens junctions [53, 54].
On the other hand, Rho GTPases, including Cdc42, Rac1,
and RhoA, have all been described to regulate adherens
junctions [55, 56]. The majority of previously published
data showed that the internalized E-cadherin induced by
Ca2+ depletion was either recycled back to the plasma
membrane or transiently maintained in endosomes of the
cells [31, 57]. Given the roles of Cdc42, Src, and EGFR in
adherens junction dynamics, it was studied whether they
cooperatively contribute to the dissolution of adherens junc-
tions, leading to E-cadherin ubiquitination and degradation.
They demonstrated that after Ca2+ depletion Cdc42 was
activated and in consequence it was initiated the activation
of EGFR and Src. Activated Src, in turn, tyrosine phosphor-
ylate E-cadherin, leading to Hakai-mediated E-cadherin
ubiquitination. Furthermore, they reported that Cdc42 binds
to E-cadherin in a GTP-dependent manner and that this
binding is essential for Cdc42 to induce the dissolution of
adherens junctions [52] (Fig. 3a).
On the other hand, the role of Rack1 in integrin-mediated
cell adhesion is well established; however, the function in
cell–cell adhesion through E-cadherin was not clear.
RACK1 is one of a group of PKC-interacting proteins
collectively called receptors for activated c-kinases
(RACKs). It was also previously reported that Rack1 acts
as a substrate and inhibitor of Src [58–60], regulating cell
growth through the inhibition of Src activity at G1 and
mitotic cell-cycle checkpoints and cell survival pathways
[61–63]. Taken in consideration these premises, in 2011, it
was addressed the effect of Rack1 on Src signaling and its
function on E-cadherin-mediated cell–cell adhesions [64]. It
was shown that Rack1 promotes cell–cell adhesion by sta-
bilizing E-cadherin and catenins at cell–cell junctions and
reduces invasive potential of colon carcinoma cells. Rack1
suppresses the tyrosine phosphorylation of E-cadherin and
its binding catenins, attenuating the downstream ubiquitina-
tion of E-cadherin, by disrupting Src–E-cadherin–Hakai
interactions, and endocytosis of E-cadherin. In consequence,
it promotes the reassembly of cell–cell contacts. Moreover,
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Fig. 2 A schematic domain structure of c-Cbl and Hakai proteins. a
Domain structure of c-Cbl protein contain a phophotyrosin-binding
domain (pTyr-B), a RING-finger domain, a proline-rich region, and a
lucine zipper (Leu-Z) domain. b Molecular structure of E3 ubiquitin-
ligase Hakai. A novel domain, HYB (Hakai pTyr-binding) consist of a
pair of monomers arranged in an anti-parallel configuration. Each
monomer consists of two zinc-finger domains: a RING finger domain
and a short pTyr-B domain that incorporates a novel, atypical Zn-finger
coordination motif. Both domains are important for dimerization
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it was demonstrated that Rack1 also block HGF-induced
cell scattering by inhibiting E-cadherin endocytosis and
junctional disassembly. Therefore, Rack1 targets both
Src- and growth-factor-dependent pathways of E-cadherin
endocytosis to promote cell–cell adhesion [64], (Fig. 3a).
Given the increasing recognized importance of the EMT
process during cancer progression (e.g., from benign ade-
noma to metastasic carcinoma) several groups have also
focused in studying the induction of EMT in response to
different signaling pathway and its influence on the E-
cadherin downregulation through Hakai action. It is well
established that tumor growth factor β (TGFβ) signaling
plays an important role in EMT [65]. In fact, adding TGFβ
to epithelial cells in culture is a convenient way to induce
EMT in various epithelial cells. In several epithelial models,
cooperation of the Raf/ERK/MAPK pathways and TGFβ
signaling is required for induction and maintenance of EMT
in vitro and in vivo [66, 67]. Janda et al. have demonstrated
how MAPK pathway and TGFβ signaling crosstalk to reg-
ulate E-cadherin expression at the initial phases of EMT
[68]. They have shown that E-cadherin is downregulated
at posttranslational level at the onset of the EMT and not at
transcriptional level, as it happens to the majority of genes
targets regulated through the cooperation between TGFβ
and Raf. This is due to an enhanced endocytosis and lyso-
somal degradation induced by synergistic activation of both
pathways. Moreover, they demonstrated that Raf and TGFβ
also cooperate in the induction of E-cadherin monoubiquiti-
nation; this effect is explained by TGFβ-dependent tran-
scriptional induction of the E3 ubiquitin ligase Hakai and
the Raf-dependent tyrosine phosphorylation of E-cadherin.
Although Raf cannot directly phosphorylate E-cadherin
on tyrosines, an increase in tyrosine phosphorylation
upon Raf hyperactivation suggest that Raf/MAPK path-
way triggers a multitude of tyrosine kinases, such as Src
that may directly phosphorylate E-cadherin (Fig. 3b).
However, they suggested that additional mechanism
may exist to induce lysosomal degradation and/or pro-
teolytic cleavage of E-cadherin under the cooperative
action of Raf and TGFβ as ubiquitin tagging is not
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sufficient for E-cadherin degradation [68]. Taken all
these publications, Hakai seems to be involved down-
stream of important signaling pathways involved during
tumor progression and in consequence more studies are
required to elucidate the emerging role for Hakai as a
potential therapeutic target.
6 Hakai downstream of Slit-Robo signaling
It is well established that the Slits secreted proteins guide
neuronal and leukocyte migration through their Roundabout
(Robo) transmembrane receptors [69, 70]. Moreover, it has
been reported that Slit proteins secreted by solid tumors
binds to Robo1 expressed in vascular and lymphatic
endothelial cells to stimulate angiogenesis and lymphan-
giogenesis [71, 72]. Slit2 mediates directional migration
of glioma cells [73] and its expression is elevated in
human colorectal carcinoma tissues and cell lines [71]
and Robo1 was found upregulated in colorectal carcino-
ma tissues, suggesting the possibility of an autocrine
mechanism through which colorectal carcinoma cells
secrete Slit2 for signaling through Robo1 expressed on
these same cells. Zhou et al. investigated the molecular
mechanism of autocrine Slit-Robo signaling to induce
malignant transformation during pathogenesis of colo-
rectal epithelial cell carcinoma [74]. They found that
the overexpression of Slit2 and Robo1, and also the
treatment with ectopic Slit2 of Robo1-positive cells with
recombinant Slit1, induced EMT-like phenotype, while
knockdown of Robo1 or blockade of Slit2 binding to
Robo1 triggered the mesenchymal–epithelial transition
(MET)-like phenotype. Robo1-Slit2 recruited Hakai to
E-cadherin promoting its ubiquitination and lysosomal
degradation. These experimental finding provide evi-
dence for induction of EMT-like phenotype through
Hakai-mediated E-cadherin downregulation during epi-
thelial colorectal cell carcinogenesis by autocrine Slit-
Robo signaling (Fig. 3c). However, Slit-Robo signaling
did not significantly reduce E-cadherin levels through
transcriptional suppression of E-cadherin or its known
transcriptional repressors (Twist, Snail, Slug, or Zeb2).
In this regard, Slit-Robo may resemble TGFβ, HGF,
Wnt/Frizzled, estrogen, bone morphogenetic proteins,
and microRNAs for reversible epithelial to mesenchymal-
like transition and cell migration. These data were consistent
to the clinical analysis of 472 clinical cases, where metastasis
human colorectal carcinoma tissues samples showed an in-
crease in pan-Slit, mainly Slit2, and Robo1 expression com-
pared to non-metastasic samples. Therefore, these findings
also reinforce the possibility to investigate inhibitors of Hakai
and/or Slit-Robo signaling in clinical testing for treating colo-
rectal carcinoma.
7 Hakai functional role independent of E-cadherin
Other functional roles for Hakai have been addressed inde-
pendently of E-cadherin protein. This idea came from the
novel human Hakai substrates identified [45, 50] and also
from the observation of two RNA bands of 2.5 and 4.8 Kb
detected by northern blot in most mouse tissues (including
testis, heart, brain, spleen, lung, liver, skeletal muscle, and
kidney); moreover, mRNA Hakai was detected during de-
velopmental stages from days 7 to 17 in postnatal mice.
Furthermore, Hakai protein is ubiquitously detected even in
tissues that do not contain E-cadherin, such as endoderm
epithelia or visceral mesoderm in Drosophila, and also in
human spleen and skeletal muscle [9, 45]. Indeed, in 2009
Figueroa et al. described polypyrimidine tract-binding
protein-associated splicing factor (PSF) as a novel Hakai-
interacting protein in cells that do not contain E-cadherin,
however they did not obtain evidence showing that Hakai
induces ubiquitination of PSF. PSF was firstly identified as
an RNA-binding protein, but it was also shown to affect
multiple cellular processes, including transcription, pre-
mRNA processing, nuclear retention, or DNA relaxation
[75–77]. By using cDNA arrays, they determined various
specific PSF-associated mRNAs encoding proteins that are
involved in several cancer-related processes. Hakai affected
the ability of PSF to bind these mRNAs [78, 79]. Furthermore,
in this study it is shown that Hakai is involved in the regula-
tion of cell proliferation in an E-cadherin downregulation-
independent manner. Hakai overexpression promotes prolif-
eration of various cultured cell lines and the knockdown of
Hakai significantly suppressed proliferation of transformed
epithelial cells. Additionally, the expression of Hakai was
correlated to the proliferation rate in hyperproliferative human
tissues Hakai such as endometrium and lymph nodes. Two
proteins were proposed to influence proliferation through
Hakai: PSF and cyclin D1. They suggested that Hakai may
regulate cell proliferation by modulating PSF activity. In
Hakai-overexpressing epithelial cells, stable knockdown of
PSF partially suppressed the proliferative influence of Hakai
overexpression. Moreover, expression of a Hakai mutant lack-
ing the RING finger sequence suppressed cell proliferation,
suggesting that this region of Hakai is necessary for promoting
cell division. This Hakai mutant was able to bind PSF, indi-
cating that Hakai’s interaction with PSF alone did not promote
cell proliferation. The physical and functional interactions
between PSF and the E3 ubiquitin-ligase activity of Hakai
await further analysis. In another hand, PSF co-localizes with
Hakai in the nucleus, raising the possibility that Hakai could
play a role in the nucleus through its association with PSF [78,
79]. According to the possible role of Hakai in the nucleus,
later report shows that Hakai is a corepressor of estrogen
receptor alpha (ERα) in breast cancer cells. By transiently
transfection of Hakai, it can repress the transactivation of the
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ERα through the direct binding to the ERα and by the recruit-
ment of coactivators such as SRC-1 and GRIP-1 (also known
as SRC-2) [80]. Hakai overexpression in a tetracycline-
induced manner decreased proliferation and migration of
ERα-dependent breast cancer MCF-7 cells [80]. These results
contrast with previously reported [78] on which overexpres-
sion of Hakai increased proliferation in stable cell lines epi-
thelial MDCK. Therefore, Hakai may exert positive or
negative control of cell proliferation in different physiological
or pathological conditions. Like Hakai, some ubiquitin ligases
are reported to function as transcriptional regulators such as
E2 ubiquitin ligase BRCA1 that modulate ERα transactiva-
tion [81], or RING finger LIM domain-interacting protein that
enhanced the activation on targets genes mediated by ERα
while it inhibits transcriptional activity of LIM-HD [82].
Therefore, Hakai was proposed as corepressor of ERα playing
a role in the development and progression of breast cancer
cells. It is possible that the proline-rich domain at the C-
terminus of Hakai could be the responsible domain for the
repression activity, as this domain is commonly contained in
repression domains or near to them, as evidenced in p53 [83],
Groucho [84], and HNF4 [85]. As it was previously reported
for other E3 ubiquitin ligases [86], these findings suggest that
Hakai can have ubiquitin-independent functions in the nucle-
us or in the cytoplasm that may influence the cell phenotype,
in addition to its influence on known substrates (like E-
cadherin) or other Hakai interacting proteins.
8 Hakai and cancer: clinical applications
There are several lines of evidence that supported a multiple
function of Hakai in tumorigenesis. Firstly, it was reported
that Hakai induced anchorage-independent cell growth;
moreover, Hakai is highly upregulated in human colon and
gastric adenocarcinomas compared to normal tissues [78].
New investigations found a low expression of Hakai and E-
cadherin or an inverse correlation between both proteins,
while comparing several colon adenocarcinomas although
the meaning of these results has to be further investigated
[87]. Secondly, in epithelial cells expressing E-cadherin
shRNA do not extend spiky protrusions that are seen in
Hakai-overexpressing cells [88], suggesting that Hakai can
also affect cellular phenotypes in an E-cadherin-independent
manner. Hakai is localized at the end of the protrusion where
FAK, focal adhesion kinase, is also enriched in Hakai-
overexpressing MDCK cells, suggesting that Hakai may
be involved in regulating the dynamic extension and retrac-
tion of these structures and in influencing cell motility [78].
Hakai’s influence on cell attachment to the substrate and
invasion capacity of epithelial MDCK cells was addressed
[89]. In this system, Hakai overexpression leads to a reduc-
tion in cell adhesion to the substrate with impact on
decreasing protein levels of Paxillin, a key focal adhesion-
associated protein, although its downregulation was con-
trolled by a proteasome-independent mechanism [89]. Nev-
ertheless, further investigations of Hakai in in vitro and in
vivo model systems would lead us to validate its role during
tumorigenesis.
Taking together the previous published reports of Hakai
during tumor progression, it is increasingly apparent that
further investigations of its physiological and pathological
functional role would lead us to a novel molecular target for
cancer treatment. Up to now, there is only one reported
publication on which it is studied the molecular mechanism
involving Hakai under the action of an agent against cancer
metastasis. One emerging approach in cancer management
is the use of “nutraceuticals”, which are relatively nontoxic,
cost-effective, and physiologically bioavailable component.
Silibinin, a flavonoid from milk thistle seed extract, is a
widely consumed dietary supplement that shows a strong
efficacy both in vitro and in vivo against prostate cancer,
establishing also its implication on epithelial–mesenchymal
transition [90–92]. Despite the previous finding describing
the role of silibinin, the main molecular targets responsible
for its strong antimigratory and anti-invasive efficacy
remained inconclusive. A recent study demonstrated that
silibinin inhibits invasive and migratory potential of several
highly metastasic cell lines at nontoxic concentrations. Un-
der these conditions, an increased E-cadherin expression at
cellular membrane and an inhibition of nuclear β-catenin
level was found, accompanied to a decreased level of Hakai,
phospho Src (tyr419), Slug Snail, and phosphor-Akt (ser473)
levels, proposing these proteins as a molecular targets im-
plicated in the antimigratory and anti-invasive efficacy of
silibinin in prostate cancer cells [93]. These findings have an
important translational relevance as the concentration of
silibinin used in these studies are within the range of free
silibinin levels achieved in the plasma of pancreatic cancer
patients in a reported phase I clinical trial [94].
9 Other Hakai clinical applications
Apart from the revised functional role of Hakai in cancer, it
is also important to mention Hakai importance in other
cellular processes and diseases. In a microarray profiling
Hakai was found differentially expressed during erythroid
differentiation of murine erythroleukemia cells, suggesting
the possibility of considering Hakai as a marker for eryth-
ropoiesis [95]. Moreover, Hakai was also proposed to be
used to evaluate the mechanism of action of immunosup-
pressive chemicals on which Hakai expression could be
novel gene marker for immunosuppression in mouse lymph
node assay [96]. More importantly, there are several
reported publications that describe Hakai role in infectious
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disease. The first work describing Hakai in this process was
by Krishnan et al. [97]. By using a human genome-wide
RNAi screen they identified Hakai as a protein that affect
West Nile virus (WNV) infection. WNV is a type of virus
known as flavivirus that constitute a significant global hu-
man health problem [98]. They identified 20 ubiquitination-
related proteins involved and they proposed Hakai to be
involved in the cellular internalization of WNV. They dem-
onstrated that Hakai and the proteasome–ubiquitin system
are required for the cellular internalization of WNV [97].
This idea was controversial as later report did not support
this data suggesting that Hakai is dispensable for cellular
internalization during flavivirus entry [99], and that the
apparent role of Hakai in WNV infection proposed by
Krishnan et al. [97] could reflect an off-target effect pro-
duced by the RNA intereference screen used. They rather
support a critical role of the ubiquitin/proteasome system
during a post-entry step of the WNV life cycle, and that the
proteasome activity is required for amplification of several
flavivirus genome [99]. Still, the implication of Hakai dur-
ing WNV infectious needs to be clarified. Other important
studies on Hakai in infectious disease were reported in
Listeria monocytogenes. Upon infection Listeria leads to a
wide range of symptoms associated to listeriosis, such as
gastroenteritis, fetoplacental, and central nervous system
infections [100]. Internalization of L. monocytogenes with
non-phagocytic cells mainly occurs via two bacterial surface
proteins: internalin-A (InIA) and internalin-B (InIB) that has
E-cadherin and Met as their respective major host-cell sur-
face receptors [101, 102]. InIA interaction with E-cadherin
activates β- and α-catenin-mediated signaling pathways
involved in the formation of adherens junctions. The initial
signals triggered by the interaction of InIA with E-cadherin
enhances the internalization of E-cadherin by Src-mediated
tyrosine phosphorylation of E-cadherin followed by its
ubiquitination by ubiquitin-ligase Hakai [103]. These post-
translational modifications also occur during bacterial infec-
tions and are necessary for an efficient InIA-mediated
bacterial internalization which it was shown to be dependent
on both caveolin and clathrin. All these data document not
only how the endocytosis machinery is recruited and in-
volved in the internalization of L. monocytogenes but also
suggest a functional link between E-cadherin endocytosis
and the formation of adherens junctions in epithelial cells
[103].
10 Conclusions
Taking in consideration the last 10 years of knowledge
regarding Hakai, the acquired importance of this protein in
cancer and other diseases is increasing apparent. All these
reports point out the need to further investigate more deeply
the molecular mechanism by which Hakai mediates its
action on tumor progression, not only by its influence on
EMT though E-cadherin downregulation but also by its
influence on early stages of tumor formation. Moreover,
novel human substrates in the nucleus or in the cytoplasm
for Hakai need to be identified to clarify its influence on cell
phenotype, including cell-substrate and invasion capability
in tumor cells. Also, more investigations need to address the
apparent relevance of Hakai ubiquitin-independent func-
tions that may influence on the cell phenotype. Therefore,
Hakai can have different functional roles in different phys-
iological or pathological conditions; in consequence, it is
also important to highlight the influence of different signal-
ing pathways on Hakai and to investigate its clinical poten-
tial usefulness as therapeutic target for cancer.
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